MaxCyte Inc
NASDAQ:MXCT
MaxCyte Inc
Stock-Based Compensation
MaxCyte Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Stock-Based Compensation
$13.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
50%
|
CAGR 10-Years
63%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Stock-Based Compensation
$310m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Stock-Based Compensation
$298m
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Waters Corp
NYSE:WAT
|
Stock-Based Compensation
$54.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Stock-Based Compensation
$247m
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
21%
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
See Also
What is MaxCyte Inc's Stock-Based Compensation?
Stock-Based Compensation
13.1m
USD
Based on the financial report for Dec 31, 2024, MaxCyte Inc's Stock-Based Compensation amounts to 13.1m USD.
What is MaxCyte Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
63%
Over the last year, the Stock-Based Compensation growth was -6%. The average annual Stock-Based Compensation growth rates for MaxCyte Inc have been 18% over the past three years , 50% over the past five years , and 63% over the past ten years .
